Type III Protein Secretion Is Associated with Death in Lower Respiratory and Systemic Pseudomonas aeruginosa Infections

…, S Racine, BL Swanson, NS Revadigar… - The Journal of …, 2001 - academic.oup.com
The ability of Pseudomonas aeruginosa to secrete specific toxins using the type III–mediated
pathway has been reported. To determine the association of this phenotype with human …

Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation

D Fluyau, N Revadigar… - Therapeutic advances …, 2018 - journals.sagepub.com
Background: Benzodiazepines (BZDs) are among the most prescribed sedative hypnotics
and among the most misused and abused medications by patients, in parallel with opioids. It …

[HTML][HTML] Biochemical benefits, diagnosis, and clinical risks evaluation of kratom

D Fluyau, N Revadigar - Frontiers in psychiatry, 2017 - frontiersin.org
Background Kratom (Mitragyna speciosa) is a tropical tree with a long history of traditional
use in parts of Africa and Southeast Asia. Kratom is also known as Thom, Thang, and Biak. Its …

Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: a systematic review

D Fluyau, N Revadigar, CG Pierre - Drug and Alcohol Dependence, 2020 - Elsevier
Background Demand for treatments for severe opioid use disorder is increasing worldwide.
The current pharmacotherapy is mainly focused on opioid and adrenergic receptors. The N-…

[HTML][HTML] Substance induced mood disorders

N Revadigar, V Gupta - 2020 - europepmc.org
Objectives: Describe the epidemiology of substance/medication-induced disorders. Outline
the typical presentation of alcohol, cocaine, or opioid-induced mood disorders. Summarize …

Systematic Review and Meta‐Analysis: Treatment of Substance Use Disorder in Attention Deficit Hyperactivity Disorder

D Fluyau, N Revadigar… - The American Journal on …, 2021 - Wiley Online Library
Background and Objectives Treating substance use disorder (SUD) in patients with co‐occurring
attention deficit hyperactivity disorder (ADHD) and SUD may lower medical, psychiatric, …

Pharmacological management of psychoactive substance withdrawal syndrome

…, SC Cook, A Chima, VK Kailasam, N Revadigar - Drugs & Therapy …, 2021 - Springer
Rationale Medications are available to manage alcohol and drug withdrawal, but they are
underutilized. Only a handful, such as methadone, buprenorphine, clonidine, or …

Pharmacological class interventions for benzodiazepine withdrawal discontinuation: a meta-analysis

D Fluyau, N Revadigar, P Mitra, CG Pierre - medRxiv, 2020 - medrxiv.org
Background Long-term benzodiazepine (BZD) use may lead to dependence, addiction, and
neuropsychiatric disturbances. BZD discontinuation can cause severe withdrawal symptoms …

Designer Drugs

N Revadigar, CT Yu, I Silverstone-Simard - Substance and Non-Substance …, 2022 - Springer
Substance use, for the most part, encompasses plant products and diverted pharmaceuticals.
Other substances called designer drugs, novel psychoactive substances (bath salts/flakka, …

[BOOK][B] Substance and Non-Substance Related Addictions: A Global Approach

E Akerele - 2022 - books.google.com
This book reviews the myriad of elements that layer substance abuse disorder, a significant
public health issue. It addresses the strong stigma associated with the disease, particularly in …